These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
81 related articles for article (PubMed ID: 17520770)
21. Tolerability of a salmeterol xinafoate/fluticasone propionate hydrofluoroalkane metered-dose inhaler in adolescent and adult patients with persistent asthma: a 52-week, open-label, stratified, parallel-group, multicenter study. Cowie RL; Boulet LP; Keith PK; Scott-Wilson CA; House KW; Dorinsky PM Clin Ther; 2007 Jul; 29(7):1390-402. PubMed ID: 17825690 [TBL] [Abstract][Full Text] [Related]
22. Cold, cough, allergy, bronchodilator, and antiasthmatic drug products for over-the-counter human use; final monograph for combination drug products. Final rule. Food and Drug Administration, HHS Fed Regist; 2002 Dec; 67(246):78158-72. PubMed ID: 12508820 [TBL] [Abstract][Full Text] [Related]
23. Detection and assessment of co-association in inhalable drug particles using aerosol time-of-flight mass spectrometry. New A; Prime D; Zomer S; Elder D; Donovan R; Freney E Rapid Commun Mass Spectrom; 2008 Dec; 22(23):3873-82. PubMed ID: 19003851 [TBL] [Abstract][Full Text] [Related]
24. Prescription Drug Marketing Act Pedigree Requirements; effective date and compliance policy guide; request for comment. Final rule; announcement of effective date; notice of availability; request for comment. Food and Drug Administration, HHS Fed Regist; 2006 Jun; 71(114):34249-51. PubMed ID: 16795943 [TBL] [Abstract][Full Text] [Related]
25. Sterility requirement for aqueous-based drug products for oral inhalation. Food and Drug Administration, HHS. Final rule. Fed Regist; 2000 May; 65(103):34082-9. PubMed ID: 11010719 [TBL] [Abstract][Full Text] [Related]
26. Updating OSHA standards based on national consensus standards. final rule; confirmation of effective date. Occupational Safety and Health Administration (OSHA), Department of Labor Fed Regist; 2008 Mar; 73(51):13753-4. PubMed ID: 18464342 [TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of fluticasone propionate/salmeterol 250/50 mcg Diskus administered once daily. Kerwin EM; Nathan RA; Meltzer EO; Ortega HG; Yancey SW; Schoaf L; Dorinsky PM Respir Med; 2008 Apr; 102(4):495-504. PubMed ID: 18206361 [TBL] [Abstract][Full Text] [Related]
28. Medical devices; medical device reporting; baseline reports. Direct final rule. Food and Drug Administration, HHS Fed Regist; 2008 Jun; 73(115):33692-5. PubMed ID: 18677824 [TBL] [Abstract][Full Text] [Related]
29. A pilot study comparing the antispasmodic effects of inhaled salmeterol, salbutamol and ipratropium bromide using different aerosol devices on muscarinic bronchoconstriction in healthy cats. Leemans J; Kirschvink N; Bernaerts F; Clercx C; Cambier C; Gustin P Vet J; 2009 May; 180(2):236-45. PubMed ID: 18294877 [TBL] [Abstract][Full Text] [Related]
30. Economic assessment of initial maintenance therapy for chronic obstructive pulmonary disease. Akazawa M; Hayflinger DC; Stanford RH; Blanchette CM Am J Manag Care; 2008 Jul; 14(7):438-48. PubMed ID: 18611095 [TBL] [Abstract][Full Text] [Related]
31. Registration and reregistration application fees. Confirmation of final rule, remanded for further notice and comment, and response to comments. Drug Enforcement Administration (DEA), Justice Fed Regist; 2002 Aug; 67(154):51987-52007. PubMed ID: 12194173 [TBL] [Abstract][Full Text] [Related]
32. Revocation of status of specific products; Group A streptococcus. Direct final rule. Food and Drug Administration, HHS Fed Regist; 2005 Dec; 70(231):72197-9. PubMed ID: 16323338 [TBL] [Abstract][Full Text] [Related]
33. Comparison of hospitalizations, emergency department visits, and costs in a historical cohort of Texas Medicaid patients with chronic obstructive pulmonary disease, by initial medication regimen. Rascati KL; Akazawa M; Johnsrud M; Stanford RH; Blanchette CM Clin Ther; 2007 Jun; 29(6):1203-13. PubMed ID: 17692734 [TBL] [Abstract][Full Text] [Related]
34. Risk of hospitalizations/emergency department visits and treatment costs associated with initial maintenance therapy using fluticasone propionate 500 microg/salmeterol 50 microg compared with ipratropium for chronic obstructive pulmonary disease in older adults. Blanchette CM; Akazawa M; Dalal A; Simoni-Wastila L Am J Geriatr Pharmacother; 2008 Aug; 6(3):138-46. PubMed ID: 18775388 [TBL] [Abstract][Full Text] [Related]
35. Quality of life measurements and bronchodilator responsiveness in prescribing nebulizer therapy in COPD. Brophy C; Kastelik J; Gardiner E; Greenstone M Chron Respir Dis; 2008; 5(1):13-8. PubMed ID: 18303097 [TBL] [Abstract][Full Text] [Related]
36. Speeding up the EPA review process. Peacock M Science; 2007 Apr; 316(5821):53. PubMed ID: 17412939 [No Abstract] [Full Text] [Related]
37. Toll-free number for reporting adverse events on labeling for human drug products. Final rule. Food and Drug Administration, HHS Fed Regist; 2008 Oct; 73(209):63886-97. PubMed ID: 19112682 [TBL] [Abstract][Full Text] [Related]
38. Applications for Food and Drug Administration approval to market a new drug; postmarketing reports; reporting information about authorized generic drugs. Direct final rule. Food and Drug Administration, HHS Fed Regist; 2008 Sep; 73(189):56487-91. PubMed ID: 18985960 [TBL] [Abstract][Full Text] [Related]
39. Air-quality standards. EPA adjusts a smog standard to White House preference. Stokstad E Science; 2008 Mar; 319(5870):1602-3. PubMed ID: 18356496 [No Abstract] [Full Text] [Related]
40. Blood vessels recovered with organs and intended for use in organ transplantation. Direct final rule. Food and Drug Administration, Health Resources and Services Administration, (HHS) Fed Regist; 2006 May; 71(92):27606-10. PubMed ID: 16696153 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]